NCT00772785 (PRO-809) is a Phase 3 clinical trial of Probuphine (buprenorphine implant) in Opioid Dependency, sponsored by Titan Pharmaceuticals.

Who is sponsoring NCT00772785?

NCT00772785 is sponsored by Titan Pharmaceuticals.

What drugs are being tested in NCT00772785?

Interventions in NCT00772785: Probuphine (buprenorphine implant).

What condition does NCT00772785 study?

NCT00772785 studies Opioid Dependency.

Is NCT00772785 still recruiting?

NCT00772785 is currently terminated. Last updated 27 December 2018.

Last reviewed 2018-12-27 · How we verify

NCT00772785: PRO-809

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-label, Multi-center Extension Study of Probuphine in Patients With Opioid Dependence

Terminated Phase 3 Last updated 27 December 2018

What this trial tests

Phase 3 trial testing Probuphine (buprenorphine implant) in Opioid Dependency in 16 participants. Terminated before completion.

Timeline

1 September 2008

Primary endpoint
1 February 2009

1 February 2009

Quick facts

Lead sponsor	Titan Pharmaceuticals
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	1 September 2008
Primary completion	1 February 2009
Estimated completion	1 February 2009
Sites	1 location across United States

Drugs / interventions tested

Probuphine (buprenorphine implant) — full drug profile →

Conditions studied

Opioid Dependency — all drugs for Opioid Dependency →

Sponsor

Titan Pharmaceuticals — full company profile →

Who can join

Adults 18 to 65, any sex, with Opioid Dependency. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of adverse events
Time frame: 24 WEEKS

Sponsor's own description

Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine (buprenorphine implant) is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study will test the safety and efficacy of Probuphine in the treatment of patients with opioid dependence. Patients who have completed at least 24 weeks of treatment in the Open-Label, Multi-Center Study of Probuphine in Patients with Opioid Dependence (PRO-807 Study), will be re-treated with Probuphine over an additional 24 weeks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Titan Pharmaceuticals trials

Trials by the same sponsor.

NCT03250117 — Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole · Phase 1, PHASE2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00772785 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Titan Pharmaceuticals
Last refreshed: 27 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00772785.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing